Patrick Linson, MD, MPH, DABR

Clinical Trials, Research & Publications

A record of clinical investigation, collaboration and scholarship.

← Back to Meet Dr. Linson

Clinical trials

Principal investigator.

Closed

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogeneous Dose Distribution Study

Active

Multi-Institutional Registry for Prostate Cancer Radiosurgery/Stereotactic Radiotherapy

Closed

External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing Upfront Local Consolidative Therapy for Oligometastatic Disease

Research & publications

Selected scholarship.

Juarez JE, Romero T, Mantz CA, et al. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Advances in Radiation Oncology. 2021;6(6).
Tang C, Hoffman KE, Allen PK, et al. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2019.
Meier R, Beckman AC, Henning G, et al. Long-Term Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):E294–E295.
Kishan AU, Dang A, Katz AJ, et al. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Network Open. 2019;2(2):e188006.
Meier R, Beckman AC, Henning G, et al. Predictive Factors for Urinary Toxicity from a Multi-Center Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 2018;102(3):e129–e130.
Meier RM, Bloch DA, Cotrutz C, et al. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. International Journal of Radiation Oncology, Biology, Physics. 2018;102(2):296–303.
Linson P, Lee A, Doytchinova B, et al. Percentage of cores involved with prostate cancer: Does it add to the percent positive prostate biopsies in predicting postoperative PSA outcome for men with intermediate-risk prostate cancer? Urology. 2002;59:704–708.
Liu S, Lee I, Linson P, Ajani U, Buring JE, Hennekens CH. A prospective study of physical activity and risk of prostate cancer in US physicians. International Journal of Epidemiology. 2000;29(1):29–35.

Additional research projects

Research contributions.

Serum and cerebrospinal fluid beta-2 microglobulin levels as a predictor of HIV progression. UCSD Neurobehavioral Research Center, San Diego, California, 1992.
Cervical Cancer Prevention in Native American Women in Boston. Harvard School of Public Health, Boston, Massachusetts, 2002.